

PORTOLA PHARMACEUTICALS INC
Form SC 13G
February 13, 2019

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934
(Amendment No.)*

Portola Pharmaceuticals, Inc.
(Name of Issuer)

Common Stock, par value \$0.001 per share
(Title of Class of Securities)

737010108
(CUSIP Number)

December 31, 2018
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP
No 737010108

1. NAME OF
REPORTING
PERSONS

Cadian Capital
Management, LP

2. CHECK THE
APPROPRIATE
BOX IF A
MEMBER OF A
GROUP (SEE
INSTRUCTIONS)
(a)
(b)

3. SEC USE ONLY

4. CITIZENSHIP
OR PLACE OF
ORGANIZATION

Delaware

5. NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING
PERSON WITH

SOLE VOTING
POWER

0

6. SHARED
VOTING
POWER

6,462,605

7. SOLE
DISPOSITIVE
POWER

0

SHARED
8. DISPOSITIVE
POWER

6,462,605

AGGREGATE
AMOUNT
BENEFICIALLY
9. OWNED BY
EACH
REPORTING
PERSON

6,462,605

CHECK BOX IF
THE
AGGREGATE
AMOUNT IN
10. ROW (9)
EXCLUDES
CERTAIN
SHARES (SEE
INSTRUCTIONS)

PERCENT OF
CLASS
11. REPRESENTED
BY AMOUNT IN
ROW (9)

9.7%

TYPE OF
REPORTING
12. PERSON (SEE
INSTRUCTIONS)
IA, PN

CUSIP
No 737010108

NAME OF
1. REPORTING
PERSONS

Cadian Capital
Management GP,
LLC

CHECK THE
APPROPRIATE
2. BOX IF A
MEMBER OF A
GROUP (SEE
INSTRUCTIONS)

- (a) []
(b) []

3. SEC USE ONLY

CITIZENSHIP
4. OR PLACE OF
ORGANIZATION

Delaware

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING
PERSON WITH

5. SOLE VOTING
POWER

0

SHARED
6. VOTING
POWER

6,462,605

7. SOLE
DISPOSITIVE

POWER

0

SHARED

8. DISPOSITIVE
POWER

6,462,605

AGGREGATE
AMOUNT
BENEFICIALLY

9. OWNED BY
EACH
REPORTING
PERSON

6,462,605

CHECK BOX IF
THE
AGGREGATE
AMOUNT IN

10. ROW (9)
EXCLUDES
CERTAIN
SHARES (SEE
INSTRUCTIONS)

PERCENT OF
CLASS

11. REPRESENTED
BY AMOUNT IN
ROW (9)

9.7%

TYPE OF
REPORTING

12. PERSON (SEE
INSTRUCTIONS)
OO, HC

CUSIP
No 737010108

1. NAME OF
REPORTING
PERSONS

Eric Bannasch

2. CHECK THE
APPROPRIATE
BOX IF A
MEMBER OF A
GROUP (SEE
INSTRUCTIONS)

(a)

(b)

3. SEC USE ONLY

4. CITIZENSHIP
OR PLACE OF
ORGANIZATION

United States of
America

5. NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING
PERSON WITH

SOLE VOTING
POWER

0

6. SHARED
VOTING
POWER

6,462,605

7. SOLE
DISPOSITIVE
POWER

0

SHARED
8. DISPOSITIVE
POWER

6,462,605

AGGREGATE
AMOUNT
BENEFICIALLY
9. OWNED BY
EACH
REPORTING
PERSON

6,462,605

CHECK BOX IF
THE
AGGREGATE
AMOUNT IN
10. ROW (9)
EXCLUDES
CERTAIN
SHARES (SEE
INSTRUCTIONS)

PERCENT OF
CLASS
11. REPRESENTED
BY AMOUNT IN
ROW (9)

9.7%

TYPE OF
REPORTING
12. PERSON (SEE
INSTRUCTIONS)
IN, HC

CUSIP No 737010108

Item 1. (a). Name of Issuer:

Portola Pharmaceuticals, Inc. (the "Issuer")

(b). Address of Issuer's Principal Executive Offices:

270 E. Grant Avenue
South San Francisco, CA 94080

Item 2. (a). Name of Person Filing:

Cadian Capital Management, LP
Cadian Capital Management GP, LLC
Eric Bannasch

The filing persons named above are collectively referred to herein as the "Reporting Persons."

(b). Address of Principal Business Office, or if None, Residence:

Cadian Capital Management, LP
535 Madison Avenue
36th Floor
New York, NY 10022

Cadian Capital Management GP, LLC
535 Madison Avenue
36th Floor
New York, NY 10022

Eric Bannasch
535 Madison Avenue
36th Floor
New York, NY 10022

(c). Citizenship:

Cadian Capital Management, LP – Delaware
Cadian Capital Management GP, LLC – Delaware
Eric Bannasch – United States of America

(d). Title of Class of Securities:

Common Stock, par value \$0.001 per share ("Common Stock")

(e). CUSIP Number:

737010108

Item 3. If This Statement is filed pursuant to Rule 13d-1(b) or Rule 13d-2(b), or (c), check whether the person filing is
a

- (a) Broker or dealer registered under Section 15 of the Exchange Act (15 U.S.C. 78c).
- (b) Bank as defined in Section 3(a)(6) of the Exchange Act (15 U.S.C. 78c).
- (c) Insurance company as defined in Section 3(a)(19) of the Exchange Act (15 U.S.C. 78c).
- (d) Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
- (e) An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
- (f) An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
- (g) A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
- (h) A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);
- (i) A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j) A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
- (k) Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

Item 4. Ownership.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a) Amount beneficially owned:

Cadian Capital Management, LP – 6,462,605
Cadian Capital Management GP, LLC – 6,462,605
Eric Bannasch – 6,462,605

(b) Percent of class:

Cadian Capital Management, LP – 9.7%
Cadian Capital Management GP, LLC – 9.7%
Eric Bannasch – 9.7%

Such percentages are based on 66,434,026 shares of the Issuer's Common Stock outstanding as of November 5, 2018, as disclosed in the Issuer's Form 10-Q filed with the Securities and Exchange Commission on November 7, 2018.

(c) Number of shares as to which the person has:

Cadian Capital Management, LP

- (i) Sole power to vote or to direct the vote 0 ,
- (ii) Shared power to vote or to direct the vote 6,462,605 ,
- (iii) Sole power to dispose or to direct the disposition of 0 ,
- (iv) Shared power to dispose or to direct the disposition of 6,462,605 .

Cadian Capital Management GP, LLC

- (i) Sole power to vote or to direct the vote 0 ,
- (ii) Shared power to vote or to direct the vote 6,462,605 ,
- (iii) Sole power to dispose or to direct the disposition of 0 ,
- (iv) Shared power to dispose or to direct the disposition of 6,462,605 .

Eric Bannasch

- (i) Sole power to vote or to direct the vote 0 ,
- (ii) Shared power to vote or to direct the vote 6,462,605 ,
- (iii) Sole power to dispose or to direct the disposition of 0 ,
- (iv) Shared power to dispose or to direct the disposition of 6,462,605 .

All securities reported in this Schedule 13G are directly held by advisory clients (the "Advisory Clients") of Cadian Capital Management, LP (the "Adviser"). Pursuant to Investment Management Agreements, as amended, between the Advisory Clients and the Adviser, the Adviser exercises exclusive voting and investment power over securities directly held by the Advisory Clients. Cadian Capital Management GP, LLC is the general partner of the Adviser. Eric Bannasch is the sole managing member of Cadian Capital Management GP, LLC.

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [].

N/A

Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

All securities reported in this Schedule 13G are directly held by Advisory Clients. None of the Advisory Clients other than Cadian Fund LP individually directly holds Common Stock representing more than 5% of the Issuer's Common Stock.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

The disclosure regarding the relationships among the Reporting Persons in Item 4 is incorporated by reference herein.

Item 8. Identification and Classification of Members of the Group.

If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.

N/A

Item 9. Notice of Dissolution of Group.

Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.

N/A

Item 10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

February 13, 2019

(Date)

Cadian Capital Management, LP

By: Cadian Capital Management GP, LLC, its General Partner

By: /s/ Eric Bannasch

Eric Bannasch

Managing Member

Cadian Capital Management GP, LLC

By: /s/ Eric Bannasch

Eric Bannasch

Managing Member

/s/ Eric Bannasch

Eric Bannasch

EXHIBIT INDEX

99.1 Joint Filing Agreement, dated as of February 13, 2019, by and among the Reporting Persons

Exhibit 99.1

AGREEMENT

In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of Schedule 13G (including additional amendments thereto) with respect to the Common Stock, par value \$0.001 per share, of Portola Pharmaceuticals, Inc. This Joint Filing Agreement shall be filed as an Exhibit to such Statement. The undersigned acknowledge that each shall be responsible for the timely filing of any amendments to such joint filing and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others.

Dated: February 13, 2019

Cadian Capital Management, LP

By: Cadian Capital Management GP, LLC, its General Partner

By: /s/ Eric Bannasch

Eric Bannasch
Managing Member

Cadian Capital Management GP, LLC

By: /s/ Eric Bannasch

Eric Bannasch
Managing Member

/s/ Eric Bannasch

Eric Bannasch